Invesco LLC Reduces Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Invesco LLC decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,815 shares of the company’s stock after selling 120 shares during the period. Invesco LLC’s holdings in Medpace were worth $935,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Pallas Capital Advisors LLC lifted its holdings in Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after buying an additional 2,101 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of Medpace by 175.6% during the third quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after acquiring an additional 9,478 shares in the last quarter. Barclays PLC boosted its holdings in shares of Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after purchasing an additional 8,275 shares during the period. Oppenheimer Asset Management Inc. grew its stake in Medpace by 6.3% in the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after purchasing an additional 2,675 shares in the last quarter. Finally, CWA Asset Management Group LLC purchased a new position in Medpace during the 3rd quarter worth $1,306,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Price Performance

Medpace stock traded down $1.86 during mid-day trading on Wednesday, reaching $343.95. 16,397 shares of the company traded hands, compared to its average volume of 203,837. Medpace Holdings, Inc. has a fifty-two week low of $286.76 and a fifty-two week high of $459.77. The firm’s fifty day moving average is $341.16 and its two-hundred day moving average is $354.14. The company has a market capitalization of $10.69 billion, a price-to-earnings ratio of 30.06, a price-to-earnings-growth ratio of 1.77 and a beta of 1.36.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of recent research reports. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Robert W. Baird raised their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday. Redburn Atlantic started coverage on shares of Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price target for the company. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, Truist Financial dropped their target price on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.